Salem Chouaib – författare

Autophagy in Immune Response: Impact on Cancer Immunotherapy focuses on the status and future directions of autophagy with respect to different aspects of its interaction with the immune system and immunotherapy. The book takes scientific research in autophagy a step further by presenting reputable information on the topic and offering integrated content with advancements in autophagy, from cell biology and biochemical research, to clinical treatments. This book is a valuable source for cancer researchers, oncologists, graduate students and several members of biomedical field who are interested in learning more on the relationship between autophagy and immunotherapies.

Presents updated knowledge on autophagy at the basic level and its potential use in cancer treatment Offers the first book to cover autophagy at the interface of cell biology, immunology and tumor biology Provides a wealth of information on the topic in a coherent and comprehensive collection of contributions by world renowned scientists and investigators

Autophagy in Immune Response: Impact on Cancer Immunotherapy focuses on the status and future directions of autophagy with respect to different aspects of its interaction with the immune system and immunotherapy. The book takes scientific research in autophagy a step further by presenting reputable information on the topic and offering integrated content with advancements in autophagy, from cell biology and biochemical research, to clinical treatments. This book is a valuable source for cancer researchers, oncologists, graduate students and several members of biomedical field who are interested in learning more on the relationship between autophagy and immunotherapies.- Presents updated knowledge on autophagy at the basic level and its potential use in cancer treatment- Offers the first book to cover autophagy at the interface of cell biology, immunology and tumor biology- Provides a wealth of information on the topic in a coherent and comprehensive collection of contributions by world renowned scientists and investigators

Hypoxia-induced Tumor Heterogeneity and Immune Evasion: Clinical Interventions explores how hypoxic stress within the tumor microenvironment drives cancer progression, immune escape, and resistance to therapy. The volume integrates foundational and cutting-edge insights into tumor biology, immunology, and therapeutic innovation. It is structured into five parts, covering tumor heterogeneity, hypoxia-driven mechanisms, immune evasion, clinical diagnostics, and future directions. Topics include metabolic reprogramming, angiogenesis, immune suppression, and hypoxia-targeted therapies, with emphasis on translational relevance.By bringing together global experts to examine how hypoxia shapes tumor evolution, alters immune responses, and influences treatment outcomes, this resource benefits researchers, clinicians, and advanced students by offering a comprehensive, up-to-date synthesis of a rapidly evolving field. It supports deeper understanding of tumor complexity and equips readers with knowledge to inform experimental design, clinical strategies, and therapeutic development in oncology.Integrates hypoxia, tumor heterogeneity, and immune evasion to provide a unified framework for understanding resistance mechanisms in cancerPresents cutting-edge research and clinical insights from global experts, offering a comprehensive view of tumor microenvironment dynamicsEquips researchers and clinicians with translational strategies to design innovative immunotherapies and improve patient outcomes

This comprehensive volume explores the latest research on the mechanisms of resistance in cancer cells to CTL-mediated immunotherapy. Chapter topics discuss cell-mediated immunity as the result of cytotoxic T-lymphocytes (CTL) directed specifically against cancer cells. In addition, the volume reviews how CTL mediate the cytotoxic activity, in large part, by the indication of apoptosis; hence, tumor cells develop anti-apoptotic mechanisms and thereby, resist CTL-induced apoptosis. In order for CTL-mediated antitumor immunotherapy to be effective, it is essential that agents directed against the resistant tumor cells sensitized cancer cells for CTL-mediated apoptosis. Examples of such agents discussed in the volume include are HDAC inhibitors, proteasome inhibitors, Bcl-2 family inhibitors, PARP, antibodies, and more.